---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-001927"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2023-02-21T23:59:59+00:00"
generated_at: "2026-06-19T07:18:54.021007+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dermata Therapeutics reports FY2022 cash of $6.2M; plans DMT310 Phase 3 in 2H 2023

## Summary
- Cash and equivalents $6.2M at Dec 31, 2022, down from $10.8M a year earlier.
- R&D expenses $5.7M in FY2022 vs $3.5M in FY2021, driven by DMT310 clinical/CMC costs.
- Cash expected to fund operations into Q3 2023; no revenue reported.
- End-of-Phase 2 meeting with FDA for DMT310 (acne) expected in Q2 2023; Phase 3 start in H2 2023.
- DMT410 partnership discussions ongoing for topical botulinum toxin delivery.

## SEC filing metadata
- accession: 0001654954-23-001927
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2023-02-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000165495423001927/0001654954-23-001927-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000165495423001927/drma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-001927
- JSON: https://secwatch.observer/filing/0001654954-23-001927.json
- Plain text: https://secwatch.observer/filing/0001654954-23-001927.txt

## Key facts
- Earnings Releases
  Dermata Therapeutics, Inc. reported financial results for the year ended December 31, 2022.
  - Period: the year ended December 31, 2022
  - Result: reported results
  source text: On February 21, 2023, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1853816/000165495423001927/0001654954-23-001927-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.